A simple blood test measuring two forms of tau protein could soon replace expensive brain scans and painful spinal taps as the standard way to detect and stage Alzheimer's disease. Scientists tested this approach on more than 1,000 patients—including people with no cognitive problems, mild cognitive impairment, Alzheimer's dementia, and other neurodegenerative diseases—and found that the blood-based staging matched the accuracy of PET brain scans, one of the most precise imaging tools available today.
For decades, diagnosing Alzheimer's has required either invasive procedures or high-cost imaging. A positive diagnosis or assessment of disease progression could mean a trip to a specialized medical center, hours in a scanner, or a needle in the spine. These barriers have made it difficult for many people—especially those in rural areas or with limited resources—to access the biological testing that determines whether they have Alzheimer's and how far it has progressed. This new blood test promises to democratize access to that critical information.
Dr. Randy D'Amico, director of the Brain and Spine Metastasis Program of Neurosurgery at Northwell Lenox Hill Hospital in New York City, praised the breakthrough while cautioning that larger studies are needed. "If the data hold up in bigger studies, I think it can really dramatically expand access to biological Alzheimer's testing, which is a big deal," he said. The implications extend beyond mere convenience. By enabling earlier and more accurate disease staging—similar to how cancer is staged to guide treatment—the blood test could help doctors select the right therapies for individual patients at the right moment in their disease progression.
The timing matters enormously. Recent advances in Alzheimer's medications have shown promise in slowing cognitive decline, but only when started early enough, before irreversible brain damage occurs. A widely accessible blood test could identify patients who would benefit most from these emerging treatments and monitor whether the drugs are working. "With better staging, that means you can better select targets for therapies," D'Amico explained, "and you might actually be able to prevent irreversible brain damage or at least expect better outcomes."
The research team's focus on tau protein is particularly significant. Tau is one of the hallmark proteins that accumulates in Alzheimer's brains, and measuring its different forms in blood offers a window into what's happening in the brain without requiring direct imaging. By zeroing in on just two forms of tau, the researchers created a model simple enough for routine clinical use while maintaining the precision of much more complicated tests.
Published May 26 in JAMA Neurology, this study represents a meaningful stride toward making Alzheimer's testing as straightforward as a routine blood draw at a primary care doctor's office. Yet researchers emphasize that more work lies ahead. Future studies must confirm how well the test performs in larger, more diverse patient populations to ensure it works equally well across different age groups, ethnicities, and geographic regions. The promise is clear: a future where catching Alzheimer's early and tracking its progression requires nothing more invasive than what millions of people already do at their annual checkups.